MANGOCEUTICALS, INC.
For the period ended Sep 30, 2025. Filed Nov 14, 2025.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Sep 30, 2025 · Filed Nov 14, 2025
MGRX$0.20+1.1%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Balance Sheets
| September 30, 2025 | December 31, 2024 | |
|---|---|---|
| (Unaudited) | (Audited) | |
| CURRENT ASSETS | ||
| Cash and cash equivalents | $481,281 | $58,653 |
| Prepaid expenses | 100,000 | - |
| Deposits | 16,942 | 16,942 |
| TOTAL CURRENT ASSETS | 598,223 | 75,595 |
| NON-CURRENT ASSETS | ||
| Property and equipment, net of accumulated depreciation of $757 and $2,256 | 2,049 | 2,806 |
| Right of use - asset | 11,211 | 59,493 |
| Intangible assets - acquired patents and license, net of amortization | 15,920,319 | 15,232,617 |
| TOTAL NON-CURRENT ASSETS | 15,933,579 | 15,294,916 |
| TOTAL ASSETS | $16,531,802 | $15,370,511 |
| LIABILITIES AND STOCKHOLDERS’ EQUITY | ||
| CURRENT LIABILITIES | ||
| Accounts payable and accrued liabilities | 526,964 | 837,501 |
| Payroll tax liabilities | 4,460 | - |
| Notes payable | - | 150,000 |
| Notes payable - related parties | 100,000 | - |
| Right-of-use liability - operating lease | 12,167 | 64,962 |
| Other liabilities - patent purchase payable | 160,684 | 373,000 |
| TOTAL CURRENT LIABILITIES | 804,275 | 1,425,463 |
| TOTAL LIABILITIES | 804,275 | 1,425,463 |
| COMMITMENTS AND CONTINGENCIES (SEE NOTE 11) | - | |
| STOCKHOLDERS’ EQUITY | ||
| Series B Convertible Preferred stock, (par value $0.0001), 6,000 shares authorized, 82 and 2,770 shares were issued and outstanding as of September 30, 2025 and December 31, 2024, respectively | - | - |
| Series C Convertible Preferred stock, (par value $0.0001), 6,250,000 shares authorized, 980,000 and 980,000 shares issued and outstanding as of September 30, 2025 and December 31, 2024, respectively | 98 | 98 |
| Common stock (par value $0.0001), 200,000,000 shares authorized, of which 13,883,103 and 3,245,641 shares issued and outstanding as of September 30, 2025 and December 31, 2024, respectively | 1,389 | 325 |
| Stock warrants | 324,288 | 324,288 |
| Subscription receivable | - | (1,150,000) |
| Additional paid in capital | 53,283,483 | 34,785,749 |
| Accumulated deficit | (37,877,913) | (20,004,486) |
| Accumulated other comprehensive loss | (2,079) | (9,845) |
| TOTAL STOCKHOLDERS’ EQUITY | 15,729,266 | 13,946,129 |
| Non-controlling interest | (1,739) | (1,081) |
| TOTAL STOCKHOLDERS’ EQUITY | 15,727,527 | 13,945,048 |
| TOTAL LIABILITIES AND STOCKHOLDERS’ EQUITY | $16,531,802 | $15,370,511 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.